Breadth of response for 13 expanded T-cell lines
Subject . | CD4 count . | Viral load, copies/mL . | No. of CD4 epitopes, min/max . | No. of CD8 epitopes, min/max . |
|---|---|---|---|---|
| 1 | 336 | 96 | 3/4 | 1/2 |
| 2 | 276 | < 75 | 2 | 1 |
| 3 | 473 | 8 940 | 0 | 2 |
| 4 | 980 | < 75 | 2/4 | 1 |
| 5 | 215 | < 75 | 3/5 | 2/3 |
| 6 | 308 | < 75 | 1/2 | 2/3 |
| 7 | 337 | < 75 | 2/3 | 4/6 |
| 8 | 116 | 6 299 | 1 | 1-2 |
| 9 | 217 | < 75 | 0 | 2 |
| 10 | 381 | 33 600 | 1 | 1-2 |
| 11 | 255 | < 75 | 1/2 | 3/4 |
| 12 | 505 | < 75 | 0 | 1/2 |
| 13 | 234 | 434 | 0 | 1 |
| Total | NA | NA | 16/24 | 22/31 |
Subject . | CD4 count . | Viral load, copies/mL . | No. of CD4 epitopes, min/max . | No. of CD8 epitopes, min/max . |
|---|---|---|---|---|
| 1 | 336 | 96 | 3/4 | 1/2 |
| 2 | 276 | < 75 | 2 | 1 |
| 3 | 473 | 8 940 | 0 | 2 |
| 4 | 980 | < 75 | 2/4 | 1 |
| 5 | 215 | < 75 | 3/5 | 2/3 |
| 6 | 308 | < 75 | 1/2 | 2/3 |
| 7 | 337 | < 75 | 2/3 | 4/6 |
| 8 | 116 | 6 299 | 1 | 1-2 |
| 9 | 217 | < 75 | 0 | 2 |
| 10 | 381 | 33 600 | 1 | 1-2 |
| 11 | 255 | < 75 | 1/2 | 3/4 |
| 12 | 505 | < 75 | 0 | 1/2 |
| 13 | 234 | 434 | 0 | 1 |
| Total | NA | NA | 16/24 | 22/31 |
For responses to adjacent OLPs, a minimal value (assuming that any 2 adjacent responses represent a single epitope) and a maximal value (assuming that adjacent responses represent discrete epitopes) were calculated. Limiting dilution analysis (not shown) identified discrete epitopes within adjacent OLPs recognized by some T-cell lines. There were no significant correlations between clinical parameters and breadth of expanded CD4+ or CD8+ T-cell responses (see “Patients, materials, and methods”).
NA indicates not applicable.